The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
ALPINE IMMUNE SCIENCES INC | COM | 02083G100 | 78,567,114 | 1,982,016 | SH | SOLE | 1,982,016 | 0 | 0 | ||
APOGEE THERAPEUTICS INC | COM | 03770N101 | 55,299,557 | 832,198 | SH | SOLE | 832,198 | 0 | 0 | ||
BEAM THERAPEUTICS INC | COM | 07373V105 | 70,031,518 | 2,119,598 | SH | SOLE | 2,119,598 | 0 | 0 | ||
BIOHAVEN LTD | COM | G1110E107 | 80,775,708 | 1,476,974 | SH | SOLE | 1,476,974 | 0 | 0 | ||
ELEVATION ONCOLOGY INC | COM | 28623U101 | 11,967,921 | 2,332,928 | SH | SOLE | 2,332,928 | 0 | 0 | ||
KEROS THERAPEUTICS INC | COM | 492327101 | 95,059,890 | 1,435,950 | SH | SOLE | 1,435,950 | 0 | 0 | ||
MERCK & CO INC | COM | 58933Y105 | 10,503,220 | 79,600 | SH | SOLE | 79,600 | 0 | 0 | ||
NUVALENT INC | COM | 670703107 | 107,901,627 | 1,436,964 | SH | SOLE | 1,436,964 | 0 | 0 | ||
SPYRE THERAPEUTICS INC | COM NEW | 00773J202 | 17,948,476 | 473,200 | SH | SOLE | 473,200 | 0 | 0 | ||
TOURMALINE BIO INC | COM | 89157D105 | 10,648,500 | 465,000 | SH | SOLE | 465,000 | 0 | 0 | ||
VAXCYTE INC | COM | 92243G108 | 187,907,421 | 2,750,804 | SH | SOLE | 2,750,804 | 0 | 0 | ||
XENCOR INC | COM | 98401F105 | 24,556,555 | 1,109,650 | SH | SOLE | 1,109,650 | 0 | 0 |